## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.4% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Boston Scientific Insiders Sell US$2.4m Of Stock, Possibly Signalling Caution**
- Source: Yahoo Finance | 20251204T071208 | Neutral | Relevance: 99%
-  Over the past year, insiders at Boston Scientific Corporation have sold US$2.4 million worth of stock, with the largest single sale being US$1.3 million by the Lead Independent Director. While insiders did not purchase any shares, their ownership still stands at 0.2% of the company. This selling activity may signal caution, but the large sale was near the current stock price, mitigating some of the negative implications.

**2. Boston Scientific Corporation (NYSE:BSX) Receives Consensus Recommendation of "Buy" from Analysts**
- Source: MarketBeat | 20251205T050849 | Bullish | Relevance: 98%
- Boston Scientific Corporation (NYSE:BSX) has received a consensus "Buy" recommendation from 25 analysts, with an average one-year price target of $123.77. The company recently beat Q3 earnings estimates and provided strong forward guidance for FY2025 and Q4. Notably, insiders have sold 143,095 shares valued at approximately $14.23 million over the last three months, though institutional investors have increased their holdings.

**3. Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets**
- Source: ts2.tech | 20251203T233558 | Bullish | Relevance: 98%
- This article provides a detailed snapshot of Boston Scientific (BSX) stock on December 3, 2025, highlighting recent insider sales, a significant EU device approval for its Farapoint pulsed field ablation catheter, and strong analyst price targets for 2026. It also recaps the company's Q3 2025 earnings, growth drivers, valuation, and risks, indicating a premium-valued medtech leader with bullish prospects tempered by insider selling and high valuation.

**4. Boston Scientific gets European nod for Farapoint catheter**
- Source: MassDevice | 20251204T162135 | Bullish | Relevance: 98%
- Boston Scientific recently received CE mark for its Farapoint pulsed field ablation (PFA) catheter, allowing it to be marketed in Europe for treating right atrial flutter (AFL). This expands the indications for its Farapulse PFA platform, which was initially approved for AFib. The company aims to become a top player in the electrophysiology space, leveraging the Farapoint catheter's demonstrated efficacy and safety in preventing AFL recurrence.

**5. Quantbot Technologies LP Grows Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251204T000801 | Bullish | Relevance: 98%
-  Quantbot Technologies LP increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.5% in the second quarter, now owning 163,745 shares valued at $17.59 million, making it their 25th largest holding. Wall Street analysts maintain a "Buy" consensus rating for BSX with an average price target of $123.77, following strong Q3 earnings where the company beat estimates and provided positive FY2025 guidance. However, company insiders have sold approximately 125,782 shares worth $12.47 million in the past 90 days.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $137.2B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 28.1 |
| Current P/E | 32.1 |
| YoY Growth | 14.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.6% to -3.4% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.36% (CS: 18) | Weak |
| RSI_14 | 42.3 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 0.961x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.52
- **Stop Loss:** $93.42 (4.2% risk)
- **Target:** $101.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $11,799.92
- **Portfolio %:** 11.80%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*